Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sagimet BiosciencesSTU:0O2 -1.97%18 Cash-to-Debt is 123.77 as of Jun. 2026, which is 87% below its 10-year median of 988.76. GuruFocus rates STU:0O2 with a GF Score™ of 18/100. The stock has 4 warning signs investors should review. Among 1,399 Biotechnology companies, Sagimet Biosciences ranks better than 78.34% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Sagimet Biosciences's cash to debt ratio for the quarter that ended in Jun. 2026 was 123.77.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Sagimet Biosciencescould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Sagimet Biosciences's Cash-to-Debt or its related term are showing as below:
STU:0O2'
s Cash-to-Debt Range Over the Past 10 Years
Min: 29.95 Med: 988.76 Max: 7450.19
Current: 123.78
During the past 7 years, Sagimet Biosciences's highest Cash to Debt Ratio was 7450.19. The lowest was 29.95. And the median was 988.76.
STU:0O2's Cash-to-Debt is ranked better than 78.34% of 1399
companies
in the Biotechnology industry
Industry Median: 6.49
vs STU:0O2: 123.78
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Sagimet Biosciences Cash-to-Debt Related Terms
Sagimet Biosciences Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Sagimet Biosciences's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
STU:0O2 vs CABA, OVID, QTTB: Cash-to-Debt Comparison
For the Biotechnology subindustry, Sagimet Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sagimet Biosciences Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Sagimet Biosciences's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sagimet Biosciences (STU:0O2) has a Cash-to-Debt of 123.77 as of Jun. 2026. This is 87% below median its historical median of 988.76. Over the past decade, Sagimet Biosciences' Cash-to-Debt has ranged from 29.95 to 7,450.19. According to the industry distribution chart, Sagimet Biosciences ranks #303 out of 1399 companies in the Biotechnology industry, placing it in the top 21.7%.
Is Sagimet Biosciences' Cash-to-Debt too high?
Sagimet Biosciences' current Cash-to-Debt of 123.77 is 87% below median its 10-year median of 988.76. Over the past 10 years, this metric has ranged from a low of 29.95 to a high of 7,450.19. The Biotechnology industry median Cash-to-Debt is 6.49. Sagimet Biosciences' value of 123.77 is 1807.1% above this industry median. Based on the distribution chart, Sagimet Biosciences ranks #303 out of 1399 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sagimet Biosciences has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Cash-to-Debt compare to CABA and OVID?
According to the Biotechnology industry distribution chart, Sagimet Biosciences ranks #303 out of 1399 companies for Cash-to-Debt. This places Sagimet Biosciences in the top 22% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 6.49. Sagimet Biosciences' value of 123.77 is 1807.1% above this benchmark. Historically, Sagimet Biosciences' own Cash-to-Debt has ranged from 29.95 to 7,450.19 over the past decade. While the company's 10-year median is 988.76 vs. the industry median of 6.49, Sagimet Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.49, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sagimet Biosciences's current Cash-to-Debt of 123.77 is 1807.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sagimet Biosciences's current Cash-to-Debt is 123.77, which is 87% below median its own 10-year median of 988.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current Cash-to-Debt of 123.77. The current Cash-to-Debt is 123.77, which is 87% below median its 10-year median of 988.76 and 1807.1% above the Biotechnology industry median of 6.49. Sagimet Biosciences' overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Cash-to-Debt is 123.77 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
18GF Score
Get the complete analysis for STU:0O2
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0O2 has been successfully added to your 
